Tomasz Byrski

Publications by Year

Research Areas

BRCA gene mutations in cancer, Genetic factors in colorectal cancer, DNA Repair Mechanisms, Ovarian cancer diagnosis and treatment, Cancer Genomics and Diagnostics

Most-Cited Works

• → Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial(2017)1,842 cited
• → CHEK2 Is a Multiorgan Cancer Susceptibility Gene(2004)551 cited
• → Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy(2009)505 cited
• → Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial(2021)399 cited
• → A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population(2010)341 cited
• → Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients(2008)339 cited
• → Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients(2014)266 cited
• → Founder Mutations in the BRCA1 Gene in Polish Families with Breast-Ovarian Cancer(2000)258 cited
• → Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer(2011)252 cited
• → RAD51 135G→C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies(2007)242 cited